Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. - Wikidata - awgldk - TriplyDB

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.

http://www.wikidata.org/entity/Q43843462

about

Systemic Chemotherapy in Advanced Pancreatic Cancer Genetic factors affecting patient responses to pancreatic cancer treatment Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Targeting cancers in the gastrointestinal tract: role of capecitabine Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma A phase I study of an oral simulated FOLFOX with high dose capecitabine.First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Current and emerging therapies for the treatment of pancreatic cancer.Pancreatic adenocarcinoma Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study Capecitabine: fulfilling the promise of oral chemotherapy.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.Systemic therapy for metastatic pancreatic adenocarcinoma.Recent developments in the pharmacological treatment of advanced pancreatic cancer.Advanced pancreatic cancer: is there a role for combination therapy?Review article: chemotherapy for pancreatic cancer.Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.Emerging drugs in pancreatic cancer.Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.Adjuvant and neoadjuvant treatment in pancreatic cancer Capecitabine: effective oral fluoropyrimidine chemotherapy.Capecitabine in carcinoma of the pancreas.A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.Retrospective Analysis of Capecitabine and Radiation Therapy in the Treatment of Pancreatic Cancer Pancreatic cancer--is the wall crumbling?Gemcitabine in the treatment of metastatic pancreatic cancer.First- and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum continues.Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review.Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.Safety of capecitabine: a review.

P2860

Q26750440-2AD13501-57C8-4D68-8DC0-48A7FF1C25A0 Q28075293-65C48182-5D82-4C44-8897-AAA4F46C5220 Q28534413-9FD6C3B3-BB37-49DD-BB55-AE6D8A2C5CD3 Q33398693-261C9407-8249-42E6-92EA-0ED51DE0C9D7 Q33402374-A73D952D-C78F-49FF-88B3-DDE8546550EE Q33416894-EC77ACD0-7CEC-4AFA-BD81-0C5313F6F971 Q33632330-E57C56B8-97CB-4042-8045-AE26A3421CA1 Q33916021-58607848-3CC3-4E9D-85EE-231324AD40AD Q33967458-5133CB6D-0AFE-4A0C-97EA-3C6EB5C79802 Q33973344-06C74740-DD76-4894-BE84-C1A26A4DDE7C Q34008520-2321B0DD-330F-4D46-97E5-333E92BA1ACF Q34129346-D472FBB4-2D42-4D60-A486-6121E56FD191 Q34140498-D0A7FE5C-9CE1-4F70-8677-DE2AD2499F36 Q34161303-F3018414-640A-4F76-9CD2-A80C86611A3F Q34449812-A5994DBC-C5DB-44BD-A5BC-B453C8D74CB1 Q34658293-C5102BAA-E7E9-4149-AEF7-FC23E9062F10 Q34660785-4F611FFB-868A-4B95-8BE3-98FFF59999F3 Q34818494-EC659AA5-7D7E-49A9-9251-3A0C166F3313 Q35032865-E1BFAA60-950D-41EA-BBDD-B2CAB1A4064C Q35076238-D7C73F3E-37EF-427C-97E1-0EDECB49D0D2 Q35144004-8C49FE46-A96E-4EB3-83DD-F8C02192FF24 Q35576200-5CB65717-2A35-4CED-9EF0-82D0DDC99B8C Q35599597-BBC395D3-2BF5-4D2D-863B-41CFE82B531B Q35638434-E959FCD8-B9DA-45BF-8EA6-04C8BC56E3F7 Q35779283-6438B466-B6A0-4FBF-968F-711600057DA6 Q35832274-34B72D88-C177-4BE5-8F08-1F268DD4FB16 Q35886631-22708C2C-838B-460F-B726-0CED504F3EB3 Q36164013-8F51F5BA-931B-46F2-A21B-FFE4C91831EC Q36548730-99A73BDF-60AF-4BAA-92A9-03E96FC83728 Q36557467-BF36B82A-D5C9-48BE-910D-6659A0923D78 Q36612255-57E0172A-1C68-4F55-B85E-DC21943F3E7D Q36615091-F29A8EE4-A553-4570-932F-E8C127E9F886 Q36616386-02AD354C-AE50-40AF-BED1-2BCA2B87A249 Q37009734-DE5EC399-E2AC-4B28-A1CF-BF7FAE0199E8 Q37125325-62BDD804-D22A-4AAB-9CA1-AA57243F70D5 Q37134412-70861335-72AE-4370-B884-E6A7B59261DE Q37140954-AE5D9721-C8A9-4392-951C-17CD1C7140FA Q37270388-F0FF829E-E1A2-42F1-AA22-0812976854D7 Q37696059-6F79FC4F-7663-43F9-B1EF-F5E55AE855DC Q37781051-9A18FD1E-7141-4D30-B7A9-93276F31E6DF

P2860

Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.

http://www.wikidata.org/entity/Q43843462

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Phase II study of oral capecit ...... metastatic pancreatic cancer.

@en

Phase II study of oral capecit ...... metastatic pancreatic cancer.

@nl

type

label

Phase II study of oral capecit ...... metastatic pancreatic cancer.

@en

Phase II study of oral capecit ...... metastatic pancreatic cancer.

@nl

prefLabel

Phase II study of oral capecit ...... metastatic pancreatic cancer.

@en

Phase II study of oral capecit ...... metastatic pancreatic cancer.

@nl

P1433

Q43843462-F6ACD948-19A5-4554-BA0E-8D6CDA15D4E3

P1476

Q43843462-98357ECB-579C-48C7-B96F-3BE4F940CBA4

P2093

Q43843462-09333A69-00B7-4933-A571-10D296BBFDFF

Q43843462-23EF2623-EA98-4AE2-B274-78D1121E4044

Q43843462-4E24A51C-12DB-4626-9835-371F8A9C79F8

Q43843462-B8EE23AA-B30A-4C09-913D-4377A1616579

Q43843462-BC24060C-375D-441B-9924-A8C649EF5FAD

Q43843462-F9653691-BF1D-483F-8108-07E42C5058CB

Q43843462-FCE80099-581C-4BAD-AE1C-3E6592129AE7

P304

Q43843462-903B68F7-79A3-4246-84D0-7983E1CBEA77

P31

Q43843462-986B289E-564D-4B59-A332-31AAEEDBE95B

P356

Q43843462-E985AF74-232B-4039-8A80-941801E30E1B

P407

Q43843462-648F14B1-7291-4F3A-AE95-9E908AEFAF42

P433

Q43843462-3E23982B-2001-439A-BF13-2DBB5CA7B404

P478

Q43843462-E62F058C-5354-4BD0-B2E7-171B7D48CF7A

P577

Q43843462-DCFCCAC1-CDA4-43D2-A160-2E8B7B8FF74D

P698

Q43843462-4768405E-9C5C-4741-8827-4865DEE8E48F

P356

P1433

Journal of Clinical Oncology

P1476

Phase II study of oral capecit ...... metastatic pancreatic cancer.

@en

P2093

Allen Cohn

http://www.w3.org/2001/XMLSchema#string

Jerry A Varkey

http://www.w3.org/2001/XMLSchema#string

John V Cox

http://www.w3.org/2001/XMLSchema#string

Joseph J Schulz

http://www.w3.org/2001/XMLSchema#string

Ted P Szatrowski

http://www.w3.org/2001/XMLSchema#string

Thomas H Cartwright

http://www.w3.org/2001/XMLSchema#string

Yin-Miao Chen

http://www.w3.org/2001/XMLSchema#string

P304

160-164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.20.1.160

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11773165

http://www.w3.org/2001/XMLSchema#string